跳转至内容
Merck
CN

B157

Sigma-Aldrich

BQ-788

≥95%, endothelin-B (ETRB) blocker, solid

别名:

2,6-二甲基哌啶羰基-γ-甲基-亮氨酸-Nin-(甲氧羰基)-D-色氨酸-D-Nle, N-[N-[N-[(2,6-二甲基-1-哌啶基)羰基]-4-甲基-L-亮氨酰]-1-(甲氧基羰基)-D-色氨酰]-D-正亮氨酸 钠盐

登录查看公司和协议定价

关于此项目

经验公式（希尔记法）:
C34H50N5NaO7
CAS Number:
156161-89-6
分子量:
663.78
MDL编号:
MFCD00797882
UNSPSC代码:
12352200
PubChem化学物质编号:
329773192
NACRES:
NA.32

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

Product Name

BQ-788, ≥95%, solid

质量水平

200

方案

≥95%

表单

solid

颜色

white

溶解性

acetonitrile: 0.3 mg/mL
DMSO: 1.2 mg/mL
ethanol: 1.2 mg/mL
H2O: slightly soluble

储存温度

−20°C

SMILES字符串

[Na+].CCCC[C@@H](NC(=O)[C@@H](Cc1cn(C(=O)OC)c2ccccc12)NC(=O)[C@H](CC(C)(C)C)NC(=O)N3[C@@H](C)CCC[C@H]3C)C([O-])=O

InChI

1S/C34H51N5O7.Na/c1-8-9-16-25(31(42)43)35-29(40)26(18-23-20-38(33(45)46-7)28-17-11-10-15-24(23)28)36-30(41)27(19-34(4,5)6)37-32(44)39-21(2)13-12-14-22(39)3;/h10-11,15,17,20-22,25-27H,8-9,12-14,16,18-19H2,1-7H3,(H,35,40)(H,36,41)(H,37,44)(H,42,43);/q;+1/p-1/t21-,22+,25-,26-,27+;/m1./s1

InChI key

QCVIFBRTTLMEOV-FUKQNADPSA-M

基因信息

human ... EDNRB(1910)
mouse ... EDNRB(13618)
rat ... EDNRB(50672)

正在寻找类似产品? 访问 产品对比指南

相关类别

应用

BQ-788 已被用作人气道平滑肌细胞 (HASMC)、子宫间皮细胞 (UtMC) 衍生的血管平滑肌细胞 (VSMC) 以及人脐静脉内皮细胞 (HUVEC) 的选择性内皮缩血管肽 (ETRB) 阻断剂。

生化/生理作用

选择性ETB内皮素受体拮抗剂。

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

个人防护装备

Eyeshields, Gloves, type N95 (US)

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
0000478397
0000478397
0000447589
0000447589
0000434031

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Emilia Kansanen et al.
Molecular pharmacology, 92(4), 481-490 (2017-08-06)
Nitro-fatty acids are reactive signaling mediators that are formed when unsaturated fatty acids react with nitric oxide or nitric oxide-derived species. Nitro-fatty acids can modify specific signaling pathways via post-translational modifications of Cys residues in key regulatory proteins. One of
John Gatfield et al.
PloS one, 7(10), e47662-e47662 (2012-10-19)
Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proliferation of pulmonary arterial smooth muscle cells (PASMC). The
Lenyta Oliveira Gomes et al.
The Journal of pharmacy and pharmacology, 70(7), 893-900 (2018-03-24)
This study assessed the ability of endothelin-1 (ET-1) to evoke heat hyperalgesia when injected directly into the trigeminal ganglia (TG) of mice and determined the receptors implicated in this effect. The effects of TG ETA and ETB receptor blockade on
Christophe Faisy et al.
Critical care (London, England), 15(5), R208-R208 (2011-09-15)
Lung inflation may have deleterious effects on the alveoli during mechanical ventilation. However, the consequences of stretch during excessive lung inflation on basal tone and responsiveness of human bronchi are unknown. This study was undertaken to devise an experimental model
H Karaki et al.
Biochemical and biophysical research communications, 205(1), 168-173 (1994-11-30)
The effects of a peptide, BQ-788 [N-cis-2, 6-dimethyl-piperidinocarbonyl-L-gamma-methylleucyl-D-1- methoxycarbonyltryptophanyl-D-norleucine], on isolated blood vessel and small intestine were examined. In the rat aorta, BQ-788 antagonized the endothelium-dependent, ETB1 receptor-mediated relaxation due to endothelin (ET)-3 with EC50 of 3 microM. In the
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持